Compare PHM & WST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PHM | WST |
|---|---|---|
| Founded | 1950 | 1923 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Homebuilding | Medical/Dental Instruments |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 23.5B | 20.2B |
| IPO Year | N/A | N/A |
| Metric | PHM | WST |
|---|---|---|
| Price | $118.20 | $277.47 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 13 | 8 |
| Target Price | $134.31 | ★ $345.75 |
| AVG Volume (30 Days) | ★ 1.8M | 692.4K |
| Earning Date | 01-29-2026 | 02-12-2026 |
| Dividend Yield | ★ 0.88% | 0.32% |
| EPS Growth | N/A | ★ 0.17 |
| EPS | ★ 13.01 | 6.75 |
| Revenue | ★ $17,622,999,000.00 | $3,017,900,000.00 |
| Revenue This Year | N/A | $7.01 |
| Revenue Next Year | N/A | $6.20 |
| P/E Ratio | ★ $9.12 | $40.82 |
| Revenue Growth | 1.76 | ★ 4.92 |
| 52 Week Low | $88.07 | $187.43 |
| 52 Week High | $142.11 | $348.90 |
| Indicator | PHM | WST |
|---|---|---|
| Relative Strength Index (RSI) | 39.74 | 54.79 |
| Support Level | $116.34 | $272.53 |
| Resistance Level | $119.90 | $279.01 |
| Average True Range (ATR) | 2.80 | 5.88 |
| MACD | -0.79 | 0.70 |
| Stochastic Oscillator | 12.72 | 88.61 |
PulteGroup Inc is a homebuilder in the United States. The company mainly builds single-family detached homes and offers products to entry-level, move-up, and active-adult buyers. It also offers homebuyers mortgage financing, title, and insurance agency services through its financial services segment.
West Pharmaceutical Services is based in Pennsylvania and is a key supplier to firms in the pharmaceutical, biotechnology, and generic drug industries. West sells elastomer-based packaging components (including stoppers, seals, and plungers), nonglass containment solutions, and auto-injectors for injectable drugs, which include large-molecule biologics, peptides such as GLP-1 receptor agonists, and small-molecule drugs. The company reports in two segments: proprietary products (about 80% of total revenue) and contract-manufactured products (about 20% of total revenue). It generates approximately 55% of its revenue from international markets and 45% from the United States.